Exhibit 10.30
to the Research, Option and License Agreement
dated September 29, 1994
This Amendment, dated this 23rd day of September, 2002, is by and between Œ VICAL INCORPORATED, a Delaware Corporation (“VICAL”), having a place of business located at 9373 Towne Centre Drive, Suite 100, San Diego, California 91212, USA, AVENTIS PASTEUR, a French Société Anonyme (“AvP”), having a registered head office located at 2 avenue Pont Pasteur, 69007 Lyon, France, and Ž AVENTIS PASTEUR Limited, a company organized and existing under the laws of the Province of Ontario, Canada (“AvP-Canada”) and having its principal place of business at Connaught Campus, 1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4.
WHEREAS, VICAL and AvP entered into a Research, Option and License Agreement (“the Agreement”) as of September 29, 1994, as amended by Amendment #1 dated as of September 29, 1994, by Amendment # 2 dated January 26, 1996, by Amendment # 3 dated as of April 15, 1996, and by Amendment # 4 dated December 7, 2001 (“Amendment # 4”) under which AvP was granted Options in the Field of Immunotherapeutic vaccines against cancer in humans containing the [***] and to obtain an exclusive license under certain Patent Rights and certain associated technologies owned by or licensed to VICAL; and
WHEREAS, VICAL informed AvP of its interest in reacquiring the rights related to [***]; and
WHEREAS, according to Amendment # 4, AvP’s Option Period will not expire before [***]; and
WHEREAS, AvP agrees to return its rights to [***] to VICAL;
NOW, THEREFORE, the parties agree to amend the Agreement as follows :
1. VICAL hereby requests that AvP abandons its rights to [***] before the end of the Option Period (as defined in Amendment # 4).
2. AvP hereby agrees to abandon the Option rights with respect to [***] (as described in point 3. of Amendment # 4), effective immediately.
3. In consideration of the reversion of rights, as soon as practicable upon execution of this Amendment # 5, VICAL will:
• Refund to AvP-Canada the USD [***] paid after execution of Amendment # 4; and
[***] Confidential material redacted and separately filed with the Commission.
• Pay to AvP an additional USD [***] for AvP’s administrative efforts since execution of Amendment # 4.
4. Additionally, VICAL hereby offers to AvP an Option to obtain an exclusive, worldwide, royalty bearing license to an available cancer specific antigen (antigen to be identified by a GenBank accession number) under the same terms and conditions as Amendment #4. Such Option shall expire [***] following execution of the present Amendment #5. For the purpose of this Amendment #5, “available cancer specific antigen” shall mean a cancer specific antigen that:
(i) VICAL is not pursuing either alone or with a Third Party; OR
(ii) VICAL has not granted rights to a Third Party.
5. Any provision of the Agreement not modified by this Amendment # 5 shall remain unchanged. Capitalized terms in this Amendment # 5 shall have the meaning set forth in the Agreement unless otherwise specified.
IN WITNESS WHEREOF, the parties hereto have had this Amendment # 5 executed by their authorized representatives as set forth below.
VICAL INCORPORATED |
AVENTIS PASTEUR Limited |
|||||
|
|
|
|||||
|
|
|
|||||
|
By : |
/s/ VIJAY SAMANT |
|
By : |
/s/ MARK LIEVONEN |
|
|
|
|
Vijay SAMANT |
|
Mark LIEVONEN |
|||
|
|
President and C.E.O. |
|
President |
|||
|
Date : 9/23/02 |
Date : 10/18/02 |
|||||
AVENTIS PASTEUR S.A. |
|
|||||
|
|
|
|||||
|
|
|
|||||
|
By : |
/s/DAVE WILLIAMS |
|
By : |
/s/ JIM TARTAGLIA |
|
|
|
|
Dave WILLIAMS |
|
Jim TARTAGLIA |
|||
|
|
President and CEO |
|
Vice-President Research |
|||
|
Date : 10/7/02 |
Date : 10/21/02 |
|||||
[***] Confidential material redacted and separately filed with the Commission.
2